$1.59
0.63% today
Nasdaq, Apr 02, 09:14 pm CET
ISIN
US00847G7051
Symbol
AGEN
Sector
Industry

Agenus Inc. Stock price

$1.60
-0.94 37.01% 1M
-3.50 68.63% 6M
-1.14 41.61% YTD
-10.15 86.38% 1Y
-48.84 96.83% 3Y
-43.74 96.47% 5Y
-102.03 98.46% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
+0.10 6.31%
ISIN
US00847G7051
Symbol
AGEN
Sector
Industry

Key metrics

Market capitalization $40.49m
Enterprise Value $451.36m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.36
P/S ratio (TTM) P/S ratio 0.39
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -33.81%
Revenue (TTM) Revenue $103.46m
EBIT (operating result TTM) EBIT $-124.43m
Free Cash Flow (TTM) Free Cash Flow $-158.89m
Cash position $40.44m
EPS (TTM) EPS $-10.69
P/E forward negative
P/S forward 0.38
EV/Sales forward 4.28
Short interest 14.44%
Show more

Is Agenus Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Agenus Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Agenus Inc. forecast:

1x Buy
25%
3x Hold
75%

Analyst Opinions

4 Analysts have issued a Agenus Inc. forecast:

Buy
25%
Hold
75%

Financial data from Agenus Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
103 103
34% 34%
100%
- Direct Costs 14 14
17% 17%
13%
90 90
36% 36%
87%
- Selling and Administrative Expenses 45 45
12% 12%
44%
- Research and Development Expense 156 156
34% 34%
150%
-111 -111
24% 24%
-107%
- Depreciation and Amortization 13 13
2% 2%
13%
EBIT (Operating Income) EBIT -124 -124
22% 22%
-120%
Net Profit -227 -227
8% 8%
-220%

In millions USD.

Don't miss a Thing! We will send you all news about Agenus Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agenus Inc. Stock News

Neutral
Business Wire
8 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus' neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT/BAL), in...
Neutral
Business Wire
14 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today announced the results of its national Colorectal Cancer in Focus survey, highlighting critical unmet needs and patient priorities in colorectal cancer (CRC) care. Colorectal cancer remains the second leading cause of cancer-related deaths worldwide a...
Neutral
Seeking Alpha
22 days ago
Agenus Inc. (NASDAQ:AGEN ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations, Corporate Development Garo Armen - Chairman and Chief Executive Officer Christine Klaskin - Vice President, Finance and Principal Financial and Accounting Officer Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Conferenc...
More Agenus Inc. News

Company Profile

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Head office United States
CEO Garo Armen
Employees 316
Founded 1994
Website www.agenusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today